RJA
NBRV

Raymond James & Associates’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Raymond James & Associates’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-149
Closed -$20K – 3948
2020
Q3 		$20K Sell
149
-14
-9% -$2.34K ﹤0.01% 3508
2020
Q2 		$27K Hold
163
– – ﹤0.01% 3426
2020
Q1 		$23K Buy
163
+4
+3% +$1.22K ﹤0.01% 3392
2019
Q4 		$52K Buy
+159
New +$72.9K ﹤0.01% 3547

Other funds holding NBRV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
AICPI
ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

Raymond James & Associates's NBRV Position: Q4 2020 in Review

Raymond James & Associates sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q4 2020, closing a stake of 149 shares — an estimated $20K sold.

Raymond James & Associates first reported a position in NBRV in Q4 2019 and held it in 4 quarters. The position peaked at $52K in Q4 2019. 33 funds tracked by Wall St. Rank hold NBRV as of Q4 2020.

  • Raymond James & Associates reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q4 2020 after selling out during the quarter.
  • Raymond James & Associates sold 149 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q4 2020, an estimated $20K.
  • Raymond James & Associates first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2019 and held it in 4 quarters.
  • Raymond James & Associates's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $52K in Q4 2019.
  • 33 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q4 2020.

Based on Raymond James & Associates's 13F filing for Q4 2020, filed 12 Feb 2021.